Syna Therapeutics participated in the World Biosimilar Congress USA, from 4 to 5 March in San Diego, which brought together the pioneers doing the most innovative work within the industry and across the whole value chain. This year’s World Biosimilar Congress USA saw over 700 attendees, 250 speakers and 50 exhibitors all under the slogan Cost-effective biologics for payers, prescribers and patients.
Dr Andreu Soldevila, CEO of Syna, gave a presentation entitled Small companies and biosimilars: keys to success on 5 March. The session covered cost effective CMC development programmes with high titer and yield, the manufacture with low COGS and FTO systems, smart CMC development, the smart (non) clinical programme and the regulation evolution for biosimilars for clinical trials.
“Biosimilars will have a profound impact on the pharmaceutical industry. We are happy to attend this key event because is an excellent opportunity to promote our know-how in all phases of biosimilar medicines, from development to manufacturing and commercialisation, and to discover new business opportunities in the USA” said Dr Soldevila.
Syna has extensive know-how in the development of biosimilars thanks to the strategic alliance between Reig Jofre, one of the leading groups in the European pharmaceutical sector, and biotechnology company, LeanBio, located in Barcelona.